Agensys and Seattle Genetics said that the study is designed to recruit up to 60 patients at multiple centers in the US.
ASG-5ME is an antibody-drug conjugate (ADC) targeting the SLC44A4 antigen and is being co-developed by both companies for the treatment of solid tumors.
Agensys CEO senior vice president and chief medical officer Leonard Reyno said that they believe ASG-5ME, which is an ADC designed to deliver the potent cytotoxic agent MMAE directly to tumor cells, has the potential to provide a new therapeutic option for men with advanced prostate cancer.
Seattle Genetics Research and Translational Medicine senior vice president Jonathan Drachman said that the clinical trial, together with their ongoing phase I trial of ASG-5ME for pancreatic cancer, reflects continued progress in expanding their pipeline of clinical-stage ADCs for cancer.